Fosfomycin does not reduce cytostatic activity of cis-platinum against human osteosarcoma cell lines in vitro.
Fosfomycin has been shown to ameliorate the dose-limiting ototoxicity and nephrotoxicity associated with the antineoplastic agent cis-platinum. Clinical use of fosfomycin in cis-platinum-treated tumor patients critically depends on retaining therapeutic efficacy of cis-platinum while designing modalities to reduce side effects. This study uses two independent assay systems for cell viability and proliferation; we demonstrate that cytocidal activity of cis-platinum against human osteosarcoma cell lines is not affected by various concentrations of fosfomycin up to 0.1 mg/ml in vitro. This suggests that in these cells there is no direct pharmacodynamic interaction of cis-platinum and fosfomycin with respect to mechanisms crucial for tumor kill.
Bührer
C
C
Children's Hospital, Freie Universität Berlin, Germany.
Atzpodien
J
J
Oz
S
S
Henze
G
G
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D003124:Colorimetry; D005578:Fosfomycin / Q000008:administration & dosage*; D006801:Humans; D012516:Osteosarcoma / Q000188:drug therapy*; D014407:Tumor Cells, Cultured
D005578:Fosfomycin; D002945:Cisplatin